Two-drug immune therapy for refractory blood cell disorders
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a combination of two medications—one that targets specific immune cells (CD20 antibody) and one that blocks a key enzyme in those cells (BTK inhibitor)—for people with ITP or AIHA that hasn't improved after standard treatments. The goal is to see if this combination can help control the disease and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with immune thrombocytopenic purpura (ITP) or autoimmune hemolytic anemia (AIHA).
- Your condition has not responded to at least one previous treatment.
- You are expected to live more than 12 months.
- Your liver, kidney, lung, and heart function are in good working order (for example, no severe heart disease like heart failure or recent heart attack).
- You are not pregnant or breastfeeding, and you do not have active hepatitis B or C, HIV, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (CD19 and BCMA) on immune cells. It is for adults with severe ITP that has not improved with other treatments. The goal is to reset the immune system to stop attacking platelets.
This trial tests a new type of cell therapy (CAR T cells) that targets and removes specific immune cells causing low platelets. It is for people with immune thrombocytopenia (ITP) that has not improved with standard treatments. The goal is to see if this therapy is safe and can help raise platelet counts.
This study tests an investigational drug called CHT105, given as an injection, for people with immune thrombocytopenia (ITP) that has not responded to or has come back after prior treatments. The goal is to see if it can help improve platelet counts and manage the disease.
This study tests whether adding a second medication (Iguratimod) to a lower dose of rituximab helps people with a blood condition called ITP who have not responded well to steroids. The goal is to see if the combination is more effective than rituximab alone at raising and keeping platelet counts stable.
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
Hear when a new BTK Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.